Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The study, published in the scientific journal Nature, has uncovered a genetic vulnerability present in nearly 10% of all breast cancer tumours, and found a way to target this vulnerability and selectively kill cancer cells.

Digital 3d illustration of cancer cells in human body

Each year, over five thousand newly diagnosed cases of breast cancer in the UK alone will carry this particular genetic fault, a proportion roughly double that driven by hereditary mutations such as those in the well-known BRCA genes.

A University of Oxford team of scientists led by Professor Ross Chapman (MRC Weatherall Institute of Molecular Medicine) working together with researchers working at the Johns Hopkins University School of Medicine in Baltimore, USA, discovered that cells originating from a specific subset of human breast cancer tumours, could be killed with a chemical that inhibits PLK4, an enzyme important for a specialized part of a cell called the centrosome. A cell’s centrosomes performs important functions during cell division, where it regulates the process in which copies of each chromosome are accurately segregated between two identical daughter cells. Normally, cells have safety mechanisms that protect them from losing their centrosomes. But the researchers discovered that these breast cancer cells could not survive without centrosomes.

The full story is available on the MRC Weatherall Institute of Molecular Medicine website

The story is also featured on the University of Oxford website

Similar stories

New form of gift wrap drives male reproductive success

General Research

A study from the Department of Physiology, Anatomy and Genetics (DPAG) has identified a new communication mechanism that ensures the transfer of a complex mix of signals and nutrients required for successful reproduction between males and females.

PRINCIPLE trial finds antibiotics azithromycin and doxycycline not generally effective treatments for COVID-19

Coronavirus COVID-19 General Research

In March 2020, the UK-wide Platform Randomised trial of INterventions against COVID-19 In older people (PRINCIPLE) trial was established as a flexible, platform randomised clinical trial to test a range of potential treatments for COVID-19 that might be suitable for use in the community to help people recover more quickly and prevent the need for hospital admission. The trial is one of three national platform trials for COVID-19 treatments, and complements the RECOVERY and REMAP-CAP trials that focus on hospitalised patients.

Early animal studies yield promising results for new potential COVID-19 vaccine

Coronavirus COVID-19 General Research

Studies carried out in the MRC Human Immunology Unit (MRC HIU) in collaboration with the Pirbright Institute have shown that a new potential vaccine against COVID-19, named RBD-SpyVLP, produces a strong antibody response in mice and pigs, providing vital information for the further development of the vaccine. Although this type of vaccine is not a competitor for the first wave of vaccines, it is hoped that it will be useful as a standalone vaccine or as a booster for individuals primed with a different COVID-19 vaccine.

Just over half of British Indians would take COVID vaccine

Coronavirus COVID-19 General Research

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.